Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about NKTR, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Etirinotecan Pegol (NKTR-102) | Metastasis | Phase 3 · NCT02915744 | Completed |
| Nab-paclitaxel | Metastasis | Phase 3 · NCT02915744 | Completed |
| NKTR-181 BID tablets | Low Back Pain | Phase 3 · NCT02367820 | Completed |
| Bempegaldesleukin (NKTR-214) | Melanoma | Phase 3 · NCT03635983 | Completed |
| Eribulin | Metastasis | Phase 3 · NCT02915744 | Completed |
| Avipendekin Pegol (NKTR-255) | Non-Hodgkin Lymphoma | Phase 2/3 · NCT05664217 | Terminated |
| Rezpegaldesleukin | Moderate-to-Severe Atopic Dermatitis | Phase 3 · NCT07711418 | Recruiting |
| Sunitinib | Renal Cell Carcinoma | Phase 3 · NCT03729245 | Terminated |
| Personalized Neoantigen Cancer Vaccine VB10.NEO | Locally Advanced or Metastatic Solid Tumours | Phase 1/2 · NCT03548467 | Completed |
| NKTR-181 | Osteoarthritis of the Knee | Phase 2 · NCT01619839 | Completed |
| Resiquimod Pegol (NKTR-262) | Melanoma | Phase 1/2 · NCT03435640 | Terminated |
| Irinotecan | Colorectal Cancer | Phase 2 · NCT00856375 | Completed |
| Dargistotug (M6223) | Locally Advanced or Metastatic Urothelial Carcinoma | Phase 2 · NCT05327530 | Active not recruiting |
| JB100 | Locally Advanced or Metastatic Urothelial Carcinoma | Phase 2 · NCT05327530 | Active not recruiting |
| ⁸⁹Zr-Df-IAB22M2C | Metastatic Melanoma | Phase 1 · NCT04955262 | Withdrawn |
| Mivavotinib Citrate (TAK-659) | Lymphoma, Non-Hodgkin | Phase 1 · NCT03772288 | Withdrawn |
Also used in these trials (approved or third-party drugs, not NKTR's own candidates): Vinorelbine, Nivolumab, Ixabepilone, Gemcitabine Hydrochloride, Paclitaxel, Docetaxel Anhydrous, Pembrolizumab, Cabozantinib, Talazoparib, Sacituzumab Govitecan, Pemetrexed Disodium, Atezolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
NKTR holds $1B in cash and short-term investments (as of Jun 30, 2026) and burns about $60M/quarter from operations, an estimated runway of 52.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 45 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NKTR files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR LLC | Institution (13G, 5%+) | 4,303,188 | 12.58% | 2026-03-31 |
| Two Seas Capital LP | Institution (13G, 5%+) | 3,345,978 | 9.78% | 2026-09-25 |
| BlackRock, Inc. | Institution (13G, 5%+) | 2,643,796 | 7.73% | 2026-06-30 |
| BVF PARTNERS L P/IL | Institution (13G, 5%+) | 2,391,075 | 6.99% | 2026-06-30 |
| STATE STREET CORPORATION | Institution (13G, 5%+) | 1,772,302 | 5.18% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 1,747,653 | 5.11% | 2026-06-30 |
| Howard W Robin President & CEO, Director · +242,703 options |
Insider | 54,655 | 0.16% | 2026-08-18 |
| R Scott Greer Director · +12,000 options |
Insider | 22,239 | 0.06% | 2026-09-23 |
| Mark Andrew Wilson Chief Legal Officer · +25,066 options |
Insider | 21,585 | 0.06% | 2025-11-21 |
| Roy A Whitfield Director · +12,000 options |
Insider | 21,185 | 0.06% | 2026-09-23 |
| Robert Chess Director · +12,000 options |
Insider | 19,299 | 0.06% | 2026-09-23 |
| Jonathan Zalevsky Chief R&D Officer · +62,932 options |
Insider | 9,570 | 0.03% | 2026-08-18 |
Share count 34,214,683 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NKTR and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →